Reply
Stuart C Gordon, Eduardo Bruno Martins, Leland J. Yee – 21 October 2013
The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitis
Darragh Duffy, Rasha Mamdouh, Melissa Laird, Charlotte Soneson, Lenaig Le Fouler, Maï El‐Daly, Armanda Casrouge, Jérémie Decalf, Amal Abbas, Noha Sharaf Eldin, Magnus Fontes, Mohamed Abdel‐Hamid, Mostafa K. Mohamed, Mona Rafik, Arnaud Fontanet, Matthew L. Albert – 21 October 2013 – Viral hepatitis is the leading cause of liver disease worldwide and can be caused by several agents, including hepatitis A (HAV), B (HBV), and C (HCV) virus.
Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markers
Andrea Lisotti, Francesco Azzaroli, Marco Montagnani, Giuseppe Mazzella – 21 October 2013
Higher viral load, higher hepatitis B surface antigen clearance?
Gin‐Ho Lo – 21 October 2013
Preparing for the uncertain yet inevitable: Off‐label combinations of antiviral agents in hepatitis C virus
Andrew Aronsohn, Nancy Reau, Donald Jensen – 21 October 2013
Interleukin‐22, liver progenitor cells, and liver cancer
Dechun Feng – 21 October 2013
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma
Bryan C. Fuchs, Yujin Hoshida, Tsutomu Fujii, Lan Wei, Suguru Yamada, Gregory Y. Lauwers, Christopher M. McGinn, Danielle K. DePeralta, Xintong Chen, Toshihiko Kuroda, Michael Lanuti, Anthony D. Schmitt, Supriya Gupta, Andrew Crenshaw, Robert Onofrio, Bradley Taylor, Wendy Winckler, Nabeel Bardeesy, Peter Caravan, Todd R. Golub, Kenneth K. Tanabe – 21 October 2013 – Hepatocellular carcinoma (HCC) is the most rapidly increasing cause of cancer‐related mortality in the United States.
Preparing for the uncertain yet inevitable: Off‐label combinations of antiviral agents in hepatitis C virus
Andrew Aronsohn, Nancy Reau, Donald Jensen – 21 October 2013
Defining and characterizing severe hypoxemia after liver transplantation in hepatopulmonary syndrome
Dhruv Nayyar, H. S. Jeffrey Man, John Granton, Samir Gupta – 18 October 2013 – Hepatopulmonary syndrome is defined as a triad of liver disease, intrapulmonary vascular dilatations, and abnormal gas exchange, and it carries a poor prognosis. Liver transplantation is the only known cure for this syndrome. Severe hypoxemia in the early postoperative period has been reported to be a major complication and often leads to death in this population, but it has been poorly characterized.
Multimodal therapy including liver transplantation for hepatic undifferentiated embryonal sarcoma
Ashley Walther, James Geller, Abigail Coots, Alexander Towbin, Jaimie Nathan, Maria Alonso, Rachel Sheridan, Greg Tiao – 18 October 2013 – The outcomes of hepatic undifferentiated embryonal sarcoma (HUES) have historically been limited by persistent, unresectable disease and the subsequent development of disease resistance and dissemination. We present our institutional experience with HUES and assess current treatment trends and outcomes in the era of liver transplantation. We conducted a retrospective chart review of cases presenting with HUES at our institution over the past 10 years.